RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $35

RBC Capital analyst Lisa Walter maintains Viridian Therapeutics (NASDAQ: VRDN ) with a Outperform and raises the price target from $34 to $35.